Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 5.71B +58.8% |
| Revenue (ttm) | 618.07M +44.0% |
| Net Income | -860.21M |
| EPS | -15.34 |
| Shares Out | 64.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,014 |
| Open | 86.72 |
| Previous Close | 85.81 |
| Day's Range | 86.72 - 88.41 |
| 52-Week Range | 63.23 - 130.00 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 153.43 (+74.45%) |
| Earnings Date | Nov 3, 2026 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]
Financial Performance
In 2025, Mirum Pharmaceuticals's revenue was $521.31 million, an increase of 54.74% compared to the previous year's $336.89 million. Losses were -$23.36 million, -73.43% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price target is $153.43, which is an increase of 74.45% from the latest price.
News
Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026.
Mirum announces results from Cohort 2 of Progress study of Atebrioz
Mirum Pharmaceuticals (MIRM) announced positive results from Cohort 2 of the pivotal Progress study of Atebrioz, an oral activin receptor-like kinase 2 inhibitor, in pediatric patients aged 6 to less…
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Mirum Pharmaceuticals’ brelovitug receives FDA orphan designation
Mirum Pharmaceuticals (MIRM)’ brelovitug received FDA orphan designation for the treatment of active hepatitis delta virus infection, according to a post to the agency’s website.
Mirum Pharmaceuticals price target raised to $145 from $140 at TD Cowen
TD Cowen analyst Joseph Thome raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $145 from $140 and keeps a Buy rating on the shares. The firm updated its…
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals price target raised to $156 from $136 at Stifel
Stifel raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $156 from $136 and keeps a Buy rating on the shares. The firm is citing the company’s recent clinical…
Mirum Pharmaceuticals price target raised to $146 from $135 at Evercore ISI
Evercore ISI raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $146 from $135 and keeps an Outperform rating on the shares.
Mirum Pharmaceuticals price target raised to $152 from $137 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $152 from $137 and keeps an Overweight rating on the shares. Data from the Phase 3 EXPAND study…
Mirum Pharmaceuticals price target raised to $184 from $160 at Citi
Citi raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $184 from $160 and keeps a Buy rating on the shares. The company’s positive Phase 3 results this morning…
Mirum Pharmaceuticals price target raised to $200 from $195 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $200 from $195 and keeps a Buy rating on the shares. The raised its Livmarli sales forecast and…
Mirum Pharmaceuticals Transcript: Study result
EXPAND met its primary and all prespecified secondary endpoints, with significant pruritus improvement overall and in biliary atresia. A supplemental NDA submission is planned for H1 next year.
Mirum Pharmaceuticals Press release: Study result
Mirum Pharmaceuticals issued a press release on October 12, 2026, disclosing material business information to investors.
Mirum Pharmaceuticals Slides: Study result
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 12, 2026.
Mirum Pharmaceuticals announces Phase 3 EXPAND study met primary endpoint
Mirum Pharmaceuticals (MIRM) announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare ch...
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.
Mirum Pharmaceuticals Slides: Corporate presentation
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 12, 2026.
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.
Mirum Pharmaceuticals price target raised to $155 from $135 at RBC Capital
RBC Capital raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $155 from $135 and keeps an Outperform rating on the shares as part of a broader research note…
Mirum Pharmaceuticals price target raised to $130 from $123 at Baird
Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $130 from $123 and keeps an Outperform rating on the shares.
Mirum Pharmaceuticals price target raised to $160 from $145 at Citi
Citi raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $160 from $145 and keeps a Buy rating on the shares. The firm cites the positive Phase 3 readout…
Vir Biotechnology in favorable position following Mirum data, says Needham
Mirum Pharmaceuticals (MIRM) brelovitug delivered a positive Phase 3 HDV result and supports a potential 1H27 BLA, but Vir Biotechnology’s (VIR) ele’ + tobe’ regimen remains differentiated by monthly ...
Mirum Pharmaceuticals price target raised to $195 from $140 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $195 from $140 and keeps a Buy rating on the shares. The company reported positive topline results from…
Mirum's liver infection drug lowers virus levels in late-stage study
Mirum Pharmaceuticals on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study.